Covington, KY, December 23, 2021 – Bexion Pharmaceuticals, Inc, today announced that it is presenting virtually at the Biotech Showcase™ 2022 conference with an online presentation. This year, registered attendees to Biotech Showcase can access Bexion’s recorded company presentation beginning the week of December 6th – five weeks prior to the actual event. 24×7 on-demand access allows attendees to view presentations at their convenience in case scheduling does not allow viewing during the main event week.

Dr. Ray Takigiku, CEO & President, Jim Beach, COO, and Dr. Rich Curry, Medical Consultant will be presenting Bexion Pharmaceuticals at Biotech Showcase.

Bexion is a clinical-stage oncology company whose lead candidate, BXQ-350, represents a new generation of biologic immunotherapy. BXQ-350 impacts lysosomal sphingolipid metabolism, inducing tumor cell death and imparting both innate and adaptive immune activities.

“Bexion is honored to be chosen to present at the 2022 BIoTech Showcase,” stated Dr. Ray Takigiku, CEO & President of Bexion. “Participating in this renowned industry meeting provides timely access to investors and future pharma partners.”

Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year during the course of one of the industry’s largest gatherings and busiest weeks.

“We are delighted that Bexion Pharmaceuticals will be presenting at Biotech Showcase this year,” said Sara Demy, CEO of Demy-Colton. “Biotech Showcase is a prime occasion for life science entrepreneurs and investors to come together to discover the potential of innovative technologies that will drive the future of drug discovery.”


Bexion Pharmaceuticals, a clinical-stage biopharmaceutical company, is pioneering the development of life-changing treatments by leveraging the untapped mechanisms of the lysosome.  Bexion believes the lysosome is an underexploited cellular orchestrator involved in multiple diseases. Bexion’s lead drug candidate is BXQ-350, a first-in-class biologic containing the multifunctional, lysosomal activator protein, Saposin C, and a phosphatidylserine.

BXQ-350 has demonstrated pre-clinical antitumor effects in vitro and in vivo, particularly in brain and other solid tumors, including those that may lead to brain metastases.   Bexion has completed a multi-site first-in-human Phase 1 clinical trial of BXQ-350 for solid tumors and gliomas.  Bexion is in Phase 1 for a rare pediatric brain tumor and plans to initiate two adult Phase 2 programs in 2022.

Media Contact: Margaret van Gilse ●859.757.1652 ● [email protected].

Bexion Media